Carcinoma Clinical Trials in Nanjing, Jiangsu
54 recruitingNanjing, Jiangsu, China
Showing 1–20 of 54 trials
Recruiting
Phase 3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Rectal AdenocarcinomaColon Adenocarcinoma
Merck Sharp & Dohme LLC477 enrolled124 locationsNCT06997497
Recruiting
Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Carcinoma, Non-Small Cell Lung
Mirati Therapeutics Inc.630 enrolled337 locationsNCT06875310
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer MetastaticNon-Small-Cell Lung CarcinomaNon-small Cell Carcinoma
Pfizer680 enrolled253 locationsNCT07144280
Recruiting
Phase 3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Non-small Cell Lung CancerCarcinoma, Non-Small Cell LungCarcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer714 enrolled315 locationsNCT06758401
Recruiting
Phase 3
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
Nasopharyngeal Carcinoma
Sun Yat-sen University593 enrolled26 locationsNCT06239727
Recruiting
Phase 2Phase 3
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Pancreatic Ductal Adenocarcinoma
Bristol-Myers Squibb470 enrolled277 locationsNCT07076121
Recruiting
Phase 2
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
Gastric CancerEsophagogastric Junction Adenocarcinoma
Zekuan Xu30 enrolled1 locationNCT06461910
Recruiting
Phase 2
Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Jiangsu Cancer Institute & Hospital22 enrolled1 locationNCT07435454
Recruiting
Phase 1
MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
Unresectable Hepatocellular Carcinoma (HCC)Hepatoma
Suzhou Mednovo Yi Medical Technology Co., Ltd.40 enrolled8 locationsNCT07391839
Recruiting
Phase 2
Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma
HCC - Hepatocellular Carcinoma
Zhejiang Hisun Pharmaceutical Co. Ltd.75 enrolled1 locationNCT07310173
Recruiting
Phase 2
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
Hepatocellular Carcinoma (HCC)
Abbisko Therapeutics Co, Ltd141 enrolled51 locationsNCT07327034
Recruiting
Phase 2
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Advanced CholangiocarcinomaFGFR2 FusionsGene Rearrangement
Taiho Oncology, Inc.120 enrolled65 locationsNCT05727176
Recruiting
Phase 2
β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Peking Union Medical College Hospital158 enrolled3 locationsNCT07317414
Recruiting
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
Renal Cell CarcinomaCarcinomaKidney Cancer+2 more
Jinling Hospital, China450 enrolled1 locationNCT05917106
Recruiting
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
CarcinomaCarcinoma, Renal CellNeoplasms+10 more
Jinling Hospital, China39 enrolled1 locationNCT06676527
Recruiting
Phase 2
Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma
Bladder CancerNeuroendocrine Carcinoma of the Bladder
RenJi Hospital22 enrolled5 locationsNCT06091124
Recruiting
Phase 2
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
ThymomaThymic Carcinoma
The First Affiliated Hospital with Nanjing Medical University20 enrolled1 locationNCT06838910
Recruiting
Phase 2
A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer
Gastric Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University460 enrolled1 locationNCT07263386
Recruiting
Phase 2
PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk
Renal Cell Carcinoma (RCC)Metastatic Renal Cell Carcinoma (mRCC)
Jinling Hospital, China30 enrolled1 locationNCT07175480
Recruiting
Phase 2
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
Renal Cell CarcinomaRadiotherapyImmune Checkpoint Inhibitor
Jinling Hospital, China35 enrolled1 locationNCT06255223